#USA #New York #Kahn Swick #Charles Foti #Hims & Hers

Controversy Erupts: Hims & Hers Health Under Investigation

In a significant development for the health tech firm Hims & Hers Health, Inc. (NYSE: HIMS), legal troubles are mounting as Kahn Swick & Foti, LLC has initiated an investigation into the company's officers and directors. Led by former Louisiana Attorney General Charles C. Foti, Jr., this scrutiny arises amid claims that the company engaged in practices that compromised patient safety and violated federal regulations.

The Controversial Partnership Termination

The issues began to escalate publicly after Novo Nordisk, a prominent pharmaceutical company, announced the termination of its partnership with Hims & Hers on June 23, 2025. Novo Nordisk cited concerns over Hims' promotion and sale of compounded drugs under misleading pretenses. The collaborator revealed that Hims had allegedly “failed to adhere to the law,” particularly regarding the distribution of compounded drugs that were marketed under the guise of 'personalization.' These claims suggest that the drugs reportedly contained unsafe foreign ingredients, raising alarm bells regarding patient safety.

Following this announcement, Hims & Hers became embroiled in a securities class action lawsuit, wherein plaintiffs accused the company and some executives of failing to disclose crucial information related to the partnership with Novo Nordisk. The lawsuit outlines allegations of misrepresentation concerning the company’s business practices and future prospects, in direct violation of federal securities laws. Recently, the presiding court dismissed Hims' motion to terminate the case, allowing it to continue forward.

Investigative Focus

The investigation by Kahn Swick & Foti aims to determine if the officers and directors of Hims & Hers breached their fiduciary duties to shareholders or violated any state or federal laws. Given the serious nature of the allegations, this examination could unveil critical insights into the operational integrity of the company and its leadership.

As the investigation unfolds, Hims & Hers faces the daunting task of addressing these issues in an environment that increasingly demands transparency and accountability from health technology companies. The firm’s future hangs in the balance, particularly concerning how it manages its brand reputation amid these legal challenges.

Legal Rights for Investors

If you are a long-term shareholder of Hims & Hers and have been affected by these recent developments, Kahn Swick & Foti invites you to share any insights that may assist in their investigation. Shareholders can reach out to the firm without obligation for consultation regarding their legal rights.

About the Law Firm

Kahn Swick & Foti, LLC is recognized as one of the leading boutique securities litigation law firms in the United States. Their partners, including Foti, have a reputation for successfully advocating for investors in cases of corporate malfeasance. The firm provides a variety of services to both institutional and retail investors aiming to recover losses due to deceptive practices in the corporate sector.

For further information about the investigation or to report related insights, shareholders are encouraged to contact KSF at their toll-free hotline or visit their website.

In these uncertain times, the scrutiny on Hims & Hers highlights the need for companies in the evolving healthcare landscape to prioritize ethical practices and ensure their claims align with regulatory standards. The outcome of this investigation could serve as a pivotal moment for not just Hims & Hers but the broader telehealth industry that continues to grow at an unprecedented pace.